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ABSTRACT
Dancy, Matthew Thomas. M.S., Department of Neuroscience, Cell Biology, and
Physiology, Wright State University, 2017. Investigating the role of an SK Channel
Activator on Survival and Motor Function of the SOD1-G93A, ALS Mouse Model.
Amyotrophic Lateral Sclerosis (ALS) is a fatal, adult-onset progressive degenerative
motor neuron disease that is characterized by muscle atrophy and weakness due to
the loss of upper and lower motor neurons. Average survival time for individuals
diagnosed with the disease is three to five years; currently there is no cure and only
one drug approved by the Food and Administration (FDA). Scientists have proposed
various theories in order to solve the mystery which surrounds ALS. One of these
theories hypothesizes how hyperexcitability and excitotoxicity leads to the death of
motor neurons. In this study, we will address ways of combatting the effects of
hyperexcitability as well as excitotoxicity by targeting a specific channel type. The
channels in question are small conductance calcium activated potassium channels
(SK channels). We chose to target these channels because they directly affect the
medium after-hyperpolarization (mAHP) of the cell which controls firing rate. We
postulate that SK channels are being altered in such a way that cell firing rate has been
increased, leading to phenotypes associated with the disease such as abnormal
excitability, mitochondrial dysfunction, axonal loss motor impairment, muscle
atrophy as well as excitotoxicity, thus leading to the spread of motor neuron death.
Upon administration with a specific SK channel activator in the form of CyPPA;
improvements in motor function and survival were found. These improvements
iii

suggest that SK channels are indeed viable drug targets and specific SK channel
activators may be treatment options for individuals suffering from ALS.
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INTRODUCTION
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Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a fatal, adult-onset neurodegenerative
disease that affects upper and lower motor neurons causing weakness, paralysis,
and eventual death (Bruijn, Miller, & Cleveland, 2004). In ALS, cortical and spinal
motor neurons (MNs) degenerate progressively (Rowland & Shneider, 2001).
Survival time for ALS patients is 3-5 years and currently there is no cure (Hirtz et al.,
2007). Patients diagnosed with the illness initially suffer from muscle weakness and
tremors that later progress to paralysis (Byrne et al., 2011). Roughly 90% of all ALS
cases are of an unknown etiology and are classified as sporadic (SALS) (Simpson &
Al-Chalabi, 2006). While the remaining cases are considered familial (FALS) (GrosLouis, Gaspar, & Rouleau, 2006). FALS is inherited in a dominant manner and
approximately 20% of these are linked to mutations of Cu/Zn superoxide dismutase
type-1 enzyme (SOD1) (Rosen et al., 1993). The clinical similarity between familial
and sporadic cases of ALS indicates that although etiology may be multifactorial,
different disease-triggering factors converge on a common pathway of MN death.
To combat MN death drugs have been administered as potential treatments
to stave off disease related symptoms. Riluzole is currently the only drug FDA
approved to treat ALS (Worldwide ALS, 2015). It is known for having many actions
which include, targeting TTX sensitive Na+ channels, inhibiting kainate and NMethyl-D-aspartic acid (NMDA) receptors and activating SK channels (Dimitriadi et
al., 2013; Gurney et al., 1996). This non-specific drug, only produces modest
increases in survival of up to 2 – 3 months in ALS patients (Bensimon, Lacomblez,
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Meininger, & Group, 1994; R. G. Miller et al., 1996; R. Miller, Mitchell, Lyon, & Moore,
2002) while also producing slight extensions (~10 days) of survival in SOD1 mice
(Bellingham, 2011; Gurney et al., 1996). Interestingly little to no changes in motor
function have been reported with treatments of Riluzole (Gurney et al., 1996).
The lack of available treatments for individuals suffering from ALS makes it
important for scientists to test various therapeutic avenues with the hopes of
ameliorating the phenotypes ALS presents. Data compiled from computational
modeling in our lab predicted a downregulation of SK channel conductance.
Immunohistochemistry experiments in our lab confirmed this prediction by
showing a decrease in SK channel cluster area and density in mutant MNs as
compared to WT. This data suggested to us that SK channel could be a novel drug
target in ALS that if activated may suppress disease related symptoms.
Pharmaceutical activation with an SK channel could allow for the reduction of
glutamate-induced excitotoxicity as well as cell hyperexcitability, allowing the
preservation of neurons; thereby leading to enhanced motor function and prolonged
survival in ALS.

3

Hyperexcitability/Excitotoxicity and Motor Neuron Death
Glutamate induced excitotoxicity is the concept of neural degeneration
caused by the over-stimulation of glutamate receptors (Olney, Mcgeer, & Mcgeer,
1978). Glutamate excitotoxicity and subsequent MN death has been increasingly
recognized as an important pathophysiological factor in ALS. In addition, reduced
expression of the glutamate transporter, excitatory amino acid transporter 2
(EAAT2), has been reported in the SOD1 mouse model and in the spinal cord of ALS
patients (Philips & Robberecht, 2011; Rothstein, 1996). Increased expression of
glutamate receptors permeable to influx of Na+ and Ca2+ ions has been reported on
MNs in ALS, thus increasing susceptibility to glutamate toxicity (Williams et al.,
1997). Ultimately, an influx of Ca2+ ions through NMDA receptors occurs, resulting
in increased intracellular Ca2+ concentration and activation of Ca2+-dependent
pathways that mediate neuronal death (Choi, 1987; Meldrum & Garthwaite, 1990)
(Figure 1, A & B). It has been suggested that neuronal cell death by excitotoxicity can
be attributed to either apoptosis or necrosis (Ientile et al., 2001).
Calcium plays a vital role in the cell signaling pathway which leads to the
apoptotic cell death of MNs (Figure 2). Calcium is usually free and unbound in the
synaptic cleft after being released from presynaptic vesicles. Once glutamate has
bound to the NMDA receptors on the postsynaptic neuron, Ca2+ is free to enter the
cell (Figure 2A). Once inside the cell Ca2+ enters the endoplasmic reticulum (ER) via
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump (Joseph & Hajnóczky,
2007; Mattson & Chan, 2003). Enhanced translocation of Ca2+ from the ER to the
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mitochondria results in mitochondrial Ca2+ overload. Initiating the release of
numerous apoptotic proteins into the cytoplasm, one of which is known as
cytochrome C (CYT C) (Joseph & Hajnóczky, 2007) (Figure 2B). Coincidently,
enhanced Ca2+ efflux from the ER can also be promoted by CYT C, by directly
activating IP3 receptors which allow increased efflux of Ca2+ from the ER (Mattson &
Chan, 2003). In time mitochondrial Ca2+ overload will induce swelling of the
mitochondria leading to disturbances and eventual mitochondrial rupture. Once
ruptured, the release of apoptotic factors enters the cytosol. CYT C together with
apoptosis protease activating factor 1 (APAF-1), forms “apoptosome” which results
in the activation of procaspase-9, and in turn activation of effector caspases
(caspases-3, -6, and -7) ultimately leading to eventual cell death (Pinton, Giorgi,
Siviero, Zecchini, & Rizzuto, 2008) (Figure 2C). Execution of mitochondria-related
apoptosis can be connected with mitochondrial dysfunction, increased reactive
oxygen species (ROS) production, and alterations to Ca2+ homeostasis; all of these
pathologies are observed in the ALS phenotype which eventually leads to MN
degeneration (Mattiazzi et al., 2002; Pinton et al., 2008).
All voluntary movement relies on lower motor neurons (LMNs), which
innervate skeletal muscle fibers and act as a link between upper motor neurons
(UMNs) and muscles (Bear, Connors, & Paradiso, 2007). UMNs originate in the
motor region of the cerebral cortex; they give rise to descending tracts that
terminate on interneurons or MNs in cranial nerve motor nuclei or in spinal cord
gray matter (Fletcher, 2012; Saladin, Sullivan, & Gan, 2015). LMNs are located in
either the anterior grey column and anterior nerve roots (spinal MNs) (Fletcher,
5

2012). Eisen et al 1992 (Eisen, Kim, & Pant, 1992) suggested that increased
excitability might be a mechanism causing both UMN and LMN degeneration in ALS
(Plaitakis & Caroscio, 1987).
Excitability may be defined as the “capacity to be activated by or react to a
stimulus” (“Excitable.,” n.d.). Thus, hyperexcitability means an increased or
exaggerated response to a stimulus. An example of hyperexcitability in denervated
skeletal muscle and ALS occurs in the form of fasciculations (Mamede de Carvalho &
Swash, 2016; Neelands, Herson, Jacobson, Adelman, & Maylie, 2001). Fasciculations
are brief, spontaneous contractions affecting a small number of muscle fibers, often
causing a flicker of movement under the skin (Oxford Dictionaries, n.d.).
Fasciculation and cramp are commonly observed clinical features in ALS and are
considered to be representative features of LMN hyperexcitability (Mamede De
Carvalho & Swash, 2013). A hallmark characteristic of the disease, fasciculation
potentials (FPs) have been shown to precede the disease by many months and the
presence of FPs is commonly used as a clinical diagnostic feature (M. De Carvalho &
Swash, 2004; T. M. Li, Alberman, & Swash, 1988). With disease progression, FPs
become complex and unstable (Mamede de Carvalho & Swash, 2016), and in 2014
and 2016 Shimizu et al and Bokuda et al concluded that a high frequency of FPs
correlated with increased disease severity (Bokuda et al., 2016; Shimizu et al.,
2014). It seems that early identification of a hyperexcitable motor system might
help in the predication of the development of ALS and, may provide a chance to
make some early ”neuroprotective” intervention prior to disease onset (Mamede de
Carvalho, 2011). Interestingly, Shibuya et al 2011 suggested that fasciculations in
6

ALS are caused by reduced potassium channel clusters (Shibuya et al., 2011). A
reduction of these clusters would cause decrease K+ conductance increasing
excitability. However, increasing K+ conductance by activating channels that directly
affect the AHP could also allow for the reduction of a hyperexcitable state.
There is evidence that hyperexcitability and excitotoxicity play key roles in
the disease mechanism and Riluzole is used to suppress the effects of both of these
pathologies (Van Den Bosch, Van Damme, Bogaert, & Robberecht, 2006). However, a
number of concerns regarding therapeutic effect still remains regarding Riluzole.
Patients treated with Riluzole only see slight extensions of survival, usually only by
a few months (2 – 3) and previous studies have shown no improvements in motor
function in SOD1 mice. (Gurney et al., 1996; Lacomblez, L., Bensimon, G., Meininger,
V., Leigh, P., & Guillet, 1996; R. Miller et al., 2002). Riluzole has numerous targets,
most of which are ion channels. This suggests that the disease may be caused by a
type of channelopathy. If this is the case, discovering affected channel(s) would
improve our understanding of the disease while also leading to potential
therapeutic targets. Targeting a channel type which directly affects cell excitability
could allow for potential MN protection leading to a novel treatment.
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A

B

Adapted from Van Den Bosch et al 2006

Figure 1: Excitotoxicity and Motor Neuron Death
A. Under normal conditions, the glutamate released by the presynaptic neuron stimulates the
Ca2+-permeable AMPA receptors present in the postsynaptic motor neuron. This leads to a
moderate, non-toxic increase of the cytoplasmic Ca2+ concentration (Van Den Bosch et al 2006). B.
Damage to the EAAT2 transporter can be caused due to the presence of mutant (mt) SOD1.
Moreover, activated microglial cells can secrete substances that increase the glutamatergic
stimulation of the postsynaptic neuron. A further increase in these factors leads to an increase in
the cytoplasmic Ca2+ concentration in the postsynaptic neuron. This leads to the generation of
toxic reactive oxygen species in the mitochondria. Once the buffering capacity of the
mitochondria is exceeded, intracellular Ca2+ over-activates Ca2+ dependent enzymes. This
interferes with normal neuronal functionality leading to neuronal death and ultimately the spread
of neurodegeneration (Van Den Bosch et al 2006).

8

A

B

Ca

SERCA pumps
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Postsynaptic Neuron
Mitochondrial Ca2+ Overload
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Apoptotic Stimuli

Adapted from Van Den Bosch et al 2006,
Joseph et al 2007 & Shi et al 2004

Figure 2: Mechanism of the Mitochondrial Apoptotic Pathway
A. Binding of glutamate to the NMDA receptors and free Ca2+ entering the postsynaptic neuron. B.
Ca2+ enters the ER and mitochondria. C. Apoptotic pathway and death.
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Small Conductance Calcium Activated Potassium Channels (SK Channels)
Small conductance calcium activated potassium channels (SK channels) are
widely expressed in the central nervous system as well as α-MNs (Adelman, Maylie,
& Sah, 2012; Deardorff et al., 2013). SK channels mainly contribute to the after
hyperpolarization potential (AHP) following action potentials (APs) and suppress
firing rate (spike frequency) of neurons (Mendelowitz, 1996). This effect allows for
a regular firing pattern and a reduction in spontaneous activity preventing
hyperexcitability. SK channels are so named because they have a small conductance
of approximately 10–14 pS (Blatz, A. L., & Magleby, 1986). SK channels share the
same tetrameric architecture with voltage-dependent potassium channels. Each
subunit is composed of six transmembrane α-helical domains that are denoted S1S6. A loop between the S5 and S6 transmembrane domains forms the potassium ion
selectivity filter (Cui, Qin, Yu, Bowers, & Zhang, 2014). Most potassium selective
channels are voltage gated, however SK channels become modified due to their
response to elevated Ca2+ levels. They are highly sensitive to calcium, being
activated in the sub-micromolar range (Kohler et al., 1996) The Ca2+ binding protein
calmodulin (CaM) is constitutively associated with SK channels at the CaM-binding
domain (CaMBD). The CaMBD is located in the proximal C-terminus of the channel
subunit (Wissmann et al., 2002). Ca2+ binding to CaM induces conformational
changes in both CaM and CaMBD that subsequently trigger an opening of the
channel pore, (Schumacher, Rivard, Ba, & Adelman, 2001) allowing potassium efflux
(Figure 3). SK channels are activated by elevations in cytosolic Ca2+ from several
sources which include; voltage dependent N-type calcium (Cav1.3) channels or
10

through permeable agonist-gated ion channels, such as NMDARs and nicotinic
acetylcholine receptors (nAChrs) (Schutter & Smolen, 1998).
In many neurons a single AP or bursts of APs are followed by a prolonged
AHP. (Barrett & Barret, 1967). The AHP has several overlapping components, which
include the fast, medium and slow AHPs. SK channels have been found to be present
in most types of neurons, including MNs, and are responsible for the mediumduration postspike after hyperpolarization (mAHP) (McLarnon, 1995). Potassium
efflux through SK channels hyperpolarizes the cell, modulating cell excitability (Lam,
Coleman, Garing, & Wulff, 2013; Wulff & Köhler, 2013). The mAHP activates rapidly
and decays over several hundred milliseconds. In many cases the mAHP is blocked
by apamin, which increases excitability and identified that SK channels indeed alter
cell firing rate. These apamin sensitive SK channels can be found in a wide variety of
neurons including MNs. The contribution of SK channels to the AHP is due largely to
their activation by Ca2+ influx via Cav1.3 channels (Edgerton & Reinhart, 2003). In
LMNs there are two functionally distinct SK channel populations. Specifically, ones
that mediate the mAHP are activated by Ca2+ influx through N- and P/Q-type
Ca2+channels (X. Li & Bennett, 2007). It has been suggested that activation of SK
channels may elicit protection against glutamate-induced excitotoxicity because of
the hyperpolarizing signal SK channels produce (Benítez et al., 2011; Dolga et al.,
2008).
While SK channels have not been directly implicated in ALS, there has been
evidence that they may be a target for study. By modifying the AHP conductance SK
channels play an important role in regulating MN excitability. Elimination of SK
11

conductance abolishes the mAHP, increasing repetitive firing (X. Li & Bennett,
2007). Therefore, increasing SK conductance could decrease firing frequency in
hyperexcitable cells. This signal would allow MNs to have a normalized firing rate,
reducing spontaneous activity, alleviating metabolic demands and oxidative stress.
In ALS, protection against these pathologies would likely lead to the survival of MNs,
thus mitigating the symptoms of MN death which include paralysis and reduced
motor output.
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A

B

C

Figure 3: SK Channel Mechanism
A. N-Type Ca2+ channel opens allowing an influx of Ca2+ into the cell. B. Ca2+ binding to CaM
induces conformational changes in both CaM and CaMBD. C. This induces conformational changes
in both CaM and CaMBD that triggers an opening of the channel pore allowing K+ efflux. Activation
of SK channels regulate cell firing and excitability. Black circles indicate potassium, gray circles
indicate calcium

13

Transgenic Mouse Line SOD Mutation
To study ALS in the lab, it is common for animal transgenic lines to be
utilized. The FUS, TDP-43, C9orf72 and the SOD1 mutations are the four main genes
which are most commonly tested and each represents a form of FALS (Vajda et al.,
2017). In our behavioral drug studies we will be using one of the SOD1 mutations,
which are the most studied animal transgenic lines in the field.
SOD1 mutant lines exhibit a point mutation in the superoxidase dismutase 1
gene, which were generated by constitutively expressing mutant human SOD1 minigenes in mice (Gurney et al., 1994). Mutations in the SOD1 gene are the most studied
form of inherited ALS, accounting for ∼20% of all the FALS forms (Rosen et al.,
1993). Of all of the SOD1 mutant models, the G1H (high-copy line with 25 copies)
line of the SOD1-G93A mutant murine strain is one of the most widely characterized
and studied models of ALS currently available (Turner & Talbot, 2008). Mice
overexpressing this form of mutant SOD1 develop a phenotype similar to that of ALS
patients including motor impairment, axonal loss, MN death, muscle atrophy and
limb weakness (Fischer et al., 2004). This transgenic line is the most aggressive
form of the disease presenting a phenotype of early disease onset and rapid disease
progression. Disease onset occurs in 3 months (90 days) and has a duration of only
1-2 months (125 days); (Chiu et al., 1995). The G93A-H transgenic line, contrasts
with the low-copy G93A strain (G93A-L) which has a disease onset of 6-8 months
(170 days), and duration of 2-3 months (225 days); (Gurney, 1997; Quinlan,
Schuster, Fu, Siddique, & Heckman, 2011).
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Early observations of abnormal glutamate metabolism and decreased
glutamate transport in the brain and spinal cord of ALS patients and SOD1 mice led
to the hypothesis that the excitatory amino acid neurotransmitter glutamate may be
involved in the ALS pathogenesis (Plaitakis, 1990; Rothstein, Martin, & Kuncl, 1992).
Therefore, drugs affecting the glutamatergic system were suggested as therapeutic
agents to reduce cell firing. The reduction of firing rate of α-MN seems to be
imperative for sustaining a healthy motor system. This can be accomplished by
targeting specific channel types which alter the AHP in along with setting cell firing
rate.

15

SK Channels in the SOD1 Model
Quinlan and colleagues reported a decrease in the AHP half-duration
although no changes were found in the AHP amplitude of their neonatal; postnatal
day 10 (P10) SOD1 mutant MNs using a slice preparation (Quinlan, 2011).
Inhibition of SK channels has been shown as a source of neuromodulation of the
AHP and has been shown to increase motor neuron firing rate(Herrik et al., 2012).
AHP modulation has been linked to disease-related changes in the G93A model
(Casas et al., 2013; Herron & Miles, 2012; Saxena et al., 2013). There is also
computational evidence that reduction of the AHP may lead to persistent inward
current facilitation, leading to further increases in cell excitability (Elbasiouny,
Bennett, & Mushahwar, 2006). A reduction in AHP can cause enhanced firing rates,
leading to the development of oxidative stress (Lancelot et al 1998) and an
increased load on mitochondrial metabolism. Increased firing rates also contribute
to disturbances of the cells ion metabolism (Heath & Shaw, 2002). Measures of the
AHP (which are mediated partially by the SK) have been demonstrated to be
significantly decreased in human patients with ALS (Piotrkiewicz & HausmanowaPetrusewicz, 2011). Piotrkiewicz et al 2011 monitored single motor unit potentials
and found that patients with ALS showed increased accurances of motor unit firing
and decreased AHP when compared to healthy individuals, thus suggesting an
increase in excitability. Furthermore, a down regulation of SK (a decrease in SK
conductance) was predicted in simulations of neonatal mutant SOD1 MNs
(Elbasiouny laboratory, unpublished data). As a means of confirming this prediction,
a later study which used immunohistochemistry to stain MNs and SK channels was
16

completed (Dukkipati, 2016). It was concluded that area and density of SK channel
clusters were also reduced in SOD1-G93A mice. The decrease in these cluster
properties may have altered channel functionality leading to changes in MN
excitability.
Considering that computational modeling predicted a downregulation of SK
conductance and this prediction was confirmed using immunohistochemistry. It was
decided that CyPPA, a specific SK channel activator and Riluzole, a non-specific drug
which also activates SK channels would be administered in our behavioral drug
studies (Cao, Dreixler, Couey, & Houamed, 2002; Grunnet et al., 2001). We are
hypothesizing that treatment with an SK channel activator would extend survival
and improve motor function in the SOD1- G93A mouse model. The significance of
these studies is that we can investigate whether SK channels are potential drug
targets. We can also investigate whether the SK channel plays a vital role in the ALS
disease mechanism and test if drug specificity is importatnt for therapeutic
efectiveness.
With a channel type identified it was imperative to determine a proper time
point for drug treatment. Many labs administer treatments with hopes of improving
disease progression and survival at late time points, typically during symptom
onset. Koschnitzky et al 2014 completed similar behavioral testing with Fluoxetine
(Koschnitzky et al., 2014). Fluoxetine increases synaptic serotonin levels which also
increases spinal MN excitability. It was reported that chronic treatments with
Fluoxetine, administered from P70-end stage and P-30-endstage presented no
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impact on disease progression (Koschnitzky et al., 2014). After finding no changes
on disease progression a new 7 day dosing paradigm was then chosen at a neonatal
treatment time point (P5 – P11). This time point was chosen because Amendola and
Durand et al 2008 showed dendritic changes at this same age in SOD1 mice
(Amendola & Durand, 2008). Koschnitzky and colleagues used this information and
administered temporary neonatal drug treatments with Fluoxetine from P5-P11.
Interestingly, this treatment paradigm produced significant impairments in motor
behavior and a severe reduction in survival. They concluded that short term
neonatal interventions can affect ALS disease progression, which supports the idea
that developmental processes may contribute later in the disease (Koschnitzky et
al., 2014).
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Drug Treatments
In these studies we used two drugs which target SK channels. The first drug
chosen was (N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4amine) (CyPPA) a specific SK channel activator. CyPPA, is a small (MW: 285),
trisubstituted pyrimidine that belongs to a completely different compound class
from that of the prototype IK/SK channel activators 1-EBIO and NS309 (Hougaard et
al., 2007). CyPPA is a positive modulator of SK but not intermediate conductance
(IK) channels. It is thought that CyPPA act as an allosteric modulator of SK2/SK3
channels, which increases their sensitivity to activation by cytosolic Ca2+ (Hougaard
et al., 2007).
The use of CyPPA during in vivo preparations have produced pronounced
increases in the duration of the mAHP (Herrik et al., 2012). These increases reduced
neuron firing when compared to controls (Herrik et al., 2012). Moreover, inhibition
of SK channels by apamin, an SK channel blocker leads to faster firing rates and
increased instantaneous firing rates (Lorenzon & Foehring, 1992; Schwindt, Spain,
Foehring, Chubb, & Crill, 1988). Apamin has also been shown to block the postspike
AHP and abolishes the SK-mediated component of the AHP (Herrik et al., 2012; X. Li
& Bennett, 2007). In other studies, oral administration of CyPPA has improved
motor performance in the neurodegenerative disorder, Spinocerebellar ataxia type
2 (SCA2) and in a model of spinal muscular atrophy (SMA). (Dimitriadi et al., 2013;
Kasumu et al., 2012). These findings suggest that CyPPA may be a possible
treatment option for other neurodegenerative disorders such as ALS.
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The second drug used in these experiments was Riluzole (2-amino-6trifluromethoxy-benzothiazole) which is currently the only FDA approved drug to
treat ALS (Gurney, Fleck, Himes, & Hall, 1998; Worldwide ALS, 2015). Riluzole was
initially identified as a paralytic agent (Domino, Unna, & Kerwin, 1952) and was
found to significantly improve muscle strength and disease progression in ALS
patients (Bensimon et al., 1994; Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P.,
& Guillet, 1996). Riluzole has a variety of pharmacologic actions, including inhibition
of glutamate release from presynaptic nerve terminals (Martin, Thompson, &
Nadler, 1993), modulation of the NMDA ionotropic receptor (Debono, Le Guern,
Canton, Doble, & Pradier, 1993), stabilization of the voltage-dependent sodium
channels, (Pratt et al., 1992) and inhibition of the high affinity uptake of λaminobutyric acid (GABA), a major inhibitory neurotransmitter (Mantz,
Laudenbach, Lecharny, Henzel, & Desmonts, 1994).
In 1998 Gurney et al showed that treatment with Riluzole increases survival
of adult G93A-H mice (Gurney et al., 1998). Gurney et al treated adult animals with
Riluzole from P42 until death at an optimal dosage of 44mg/kg and saw a 10 day
increase in survival (Gurney et al., 1998), interestingly no changes in motor function
were shown in their behavioral drug studies (Gurney et al., 1996). Given that
Riluzole has numerous targets which also includes SK channels (Cao, Dreixler,
Couey, & Houamed, 2002; Grunnet et al., 2001), the mechanism of Riluzole
protection remains unclear (Bellingham, 2011; Kuo, Siddique, Fu, & Heckman, 2005;
Schuster et al., 2012). However, in 2013 Dimitriadi et al suggested that Riluzole was
beneficial in two models of SMA and works via SK channels by improving
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neuromuscular function (Dimitriadi et al., 2013). Considering that Riluzole acts via
SK channels and has been shown to have some therapeutic effect by reducing
excitability (Dimitriadi et al., 2013; Kuo et al., 2005). Perhaps treatment with CyPPA,
a more potent and specific channel activator which modifies excitability by
increasing the AHP could lead to increased motor output and prolonged survival in
ALS mice.
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Rationale
A shortening of the α-MN mAHP has been noted directly in a mouse in vitro
electrophysiological study (Quinlan et al., 2011) and indirectly in a study of human
muscular electrical activity in ALS patients (Piotrkiewicz & HausmanowaPetrusewicz, 2011). A modeling prediction from Elbasiouny et al suggested that a
downregulation of SK conductance is present in mutant neonatal SOD1 MNs
(Elbasiouny lab, unpublished results) and Dukkipati et al confirmed this prediction
using immunohistochemistry (Dukkipati, 2016).

Specific Aims
1. Investigate whether the SK Channels is an effective drug target in an ALS
mouse model.
2. Investigate whether SK channels play a major role in ALS pathogenesis.
3. Investigate whether drug specificity can affect therapeutic outcomes.

Hypothesis
Treatment with a specific SK channel activator would extend survival and
improve motor function of the SOD1-G93A ALS mouse model. Thus, it is
hypothesized that treatment with a specific SK channel activator would extend
survival and improve motor function of the SOD1-G93A ALS mouse model.
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MATERIALS AND METHODS
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Animals
SOD1-G93A-H male mice were grouped housed in barrier facilities on a
12:12-h light-dark cycle. Food and water were provided ad libitum. All mice tested
had a background of B6SJL-Tg (Jackson Laboratories, stock #002726) and were age
matched littermates. All procedures were approved by the Wright State University
LACUC. In these types of studies a minimum of twelve animals per group is
recommended to ensure minimal variability (Scott et al., 2008). We will adhere to
these guidelines and have at least twelve animals in each treatment group.
Drugs
CyPPA (Sigma-Aldrich, CAT No.5493) was administered via three separate
dosing paradigms. Treatment of CyPPA was given to neonatal mice from P5 to P20
(CyPPA P5-P20), adult mice from P90 – P96 (CyPPA P90 7 Day) and a daily dosing
paradigm starting a P90 and ending at death (P90 Daily study). During the neonatal
dosing paradigm a 16 day treatment period was chosen because SK channels are
coupled with N-type Ca2+. Since N-type Ca2+ channels mature around P18 (Inagaki &
Lee, 2013), we thought overlapping drug administration with channel maturation
during development would be key for therapeutic effects to become present. For all
studies using CyPPA drug was administered through once daily injections (14mg/kg
body weight, Intraperitoneal (IP)) or vehicle control (11% DMSO and saline – 16
Day treatment of CyPPA at P5 and 7 Day treatment of CyPPA at P90; 11% DMSO,
5% Kolliphore and Saline – Daily CyPPA treatment at P90) injections. During
preliminary testing it was found that CyPPA resulted in healthy animals not
completing the rotarod protocol 30 minutes after dosing. Animals receiving the drug
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became lethargic and motor function was significantly reduced as they fell off the
rotarod prematurely. These changes were present up to an hour after injection.
However, during experimentation drug was administered after behavioral testing to
avoid any motor performance changes caused by the drug.

Riluzole (MP Biomedicals, LLC, CAT No. 193713) was administered to
neonatal mice from P5 – P20 (Riluzole P5-P20), Drug was administered through
once daily injections (22mg/kg body weight IP) or vehicle control (0.1 Normal HCl,
diluted in water (DDI)) injections. Riluzole concentration was determined by
halving the optimal dosage reported in literature since higher dosages of 44mg/kg
and 33mg/kg was too strong and would kill the neonatal mice.

Drug

Structure

Interactions
EC50 = 6µM
Target: Activates KCA2.3, Inhibits
NaV Channels
Half Life: Unknown

CyPPA
(N-cyclohexyl-2-(3,5dimethylpyrazol-1-yl)-6methylpyrimidin-4-amine)

-Hougaard et al 2007

EC50 = 12µM
Targets: KCA2.3, TTX Sensitive Na+
channels, Inhibits kainate and
NMDA receptors, BK Channels
Half Life: 12 Hours
FDA Approved

Riluzole
(2-amino-6-trifluromethoxybenzothiazole)

- Grant et al 2010
Table 1: Drugs used during testing, along with their structure and interactions.
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Behavioral Studies: Protocol and Criteria
Behavior studies were performed every other day by individuals blinded to
genotype and drug condition. Rotarod testing and data collection started at P85 for
each drug study. Rotarod testing did not start at an earlier age because SOD and WT
mice show no differences in motor ability until symptoms become present, typically
around P90. Weight, motor function, end stage, first failure and final failure were
monitored for all mice.
Animals received a period of 4 consecutive days of training on rotarod
testing paradigm. The training period started at P72. During testing and training
animals would run on the rotarod for a total of 240seconds. The rotarod was set at
5rpm for the first 30s, then increased to 10rpm to complete the first minute. The
rotarod then increased to 15rpm for another 30s and increased to 20rpm for a full
minute. To finish testing, the rotarod was set at its maximum rotation speed of 25
rpm for 90 seconds (Table 2). The fall time was recorded via photo beam break on
the rotarod device (AccuRotor Multi-Animal Rotarod. Omnitech Electronics, Inc
(Figure 4)). Mice ran three times with at least a five minute break between runs. The
maximum time from each of the three trials was recorded to determine motor
function. Maximum time spent on the rotarod was used to prevent daily motor
performance variance. The age at which mice failed to complete the entire protocol
(240s) for each of the three trials was recorded; this was considered First failure.
Final failure was recorded when the animals failed to stay on the rotarod for <12s
for each of the three trials. Final failure was representative of the animal completing
<5% of the rotarod protocol and severe motor deficits being present (Figure 5).
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Rate of Motor Function Loss was used to determine slope of rotarod decline.
A ten percent drop from the baseline was used to ensure motor decline was present.
The lower limit of the regression test was determined when animals reached an
average of ten percent completion (Figure 5). This point was chosen due to the rapid
disease progression seen in the model. We wanted to ensure our slope was a good
representation of overall motor function.
Survival was determined when animals failed the righting reflex test. If they
could not right themselves 30s after being placed on their back the animals were
humanely euthanized.
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Figure 4: Rotarod
AccuRotor – Multi Animal Rotarod, Omnitech Electronics, Inc

Table 2: Rotarod Protocol
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Figure 5: Assessment Criteria
First failure, time point when animals no longer fully complete the rotarod protocol. Rate of
Motor Function Loss, Slope and linear fit of rotatod line. To determine slope, a baseline for motor
function was determined. A ten percent drop from the baseline was instituted to ensure motor
function decline was present. The lower limit of the regression test was determined when animals
being tested reached an average of ten percent completion. Ten percent completion is equivalent
to 24 seconds of time spent on the rotarod. This point was chosen due to the fact that many
animals drop out of the study because of rapid disease progression. Also, we wanted to ensure
our slope was a good representation of overall motor function. Final failure was recorded when
animals failed to stay on the rotarod for <12s for each of the three trials. Final failure was
representative of the animal completing <5% of the rotarod protocol and severe motor deficits
being present. Survival was determined when animals failed the righting reflex test. At this point
animals were humanely euthanized.
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Survival Analysis
The Kaplan Meier Log Rank survival test was used to analyze final failure and
overall Survival of the animals. The final failure time point is indicative of severe
gross motor deficits and a lack of motor control. Survival represents the age when
animals fail the righting reflex test. At this time point animals are humanely
euthanized.
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Statistics
Values are represented as mean ± standard error of the mean. Data, including
Kaplan Meier survival analysis was analyzed using Statistica 12. Student’s t-test
were used to analyze differences between first failure, final failure, survival and
every day the animals ran. All data had normal distributions and equal variance.
Kaplan Meier survival analysis was used to determine probability of survival for
motor function and overall survival. The Mann-Whitney U test a nonparametric
analysis was also used to analyze motor function data. Figures were made with
Matlab R2015A. P-values less than 0.05 were considered statistically significant.
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RESULTS
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NEONATAL DRUG TREATMENTS
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Study 1 - 16 Day Treatment of CyPPA starting at P5 – P20
Analysis of motor function was completed as described (Figure 6), n for the
animals receiving CyPPA was 12 and n for the animals receiving the vehicle control
animals was 13. It was found that animals receiving CyPPA presented no differences
when testing first failure using a student’s t-test (p = 0.99). First failure for both the
treatment and the vehicle control groups occurred at P111. However, significant
differences were found when testing motor function. Analysis of motor function was
completed using a student’s t-test by testing each day the animals ran. Animals
receiving CyPPA showed sustained motor function as the disease progressed.
Starting at P123 – P128 significant differences were found using a student’s t-test
(P123 - P128: p ≤ 0.0264). Analysis of the Mann-Whitney U test also showed
significant improvements in motor function between the treatment and control
vehicle groups from P125 – P128 (p ≤ 0.019). Overall, animals receiving CyPPA had
significant improvements in motor function (Figure 6).
To assess motor function, a regression test was utilized to measure the slope
of motor function decline (Figure 7). Comparison of the SOD-treated vs. the SODControl of the Regression test showed significant differences between the slopes for
CyPPA and the Vehicle Control. Slope for animals receiving CyPPA was -0.0211, R2 =
0.85, while the slope for the Vehicle Control animals was -0.0349, R2 = 0.74 (p =
0.007).
As the study progressed, animal performance continued to drop. The next
analysis completed tested final failure (Figure 8). Final failure is the age at which the
animals stopped running on the rotarod and the presence of gross motor deficits
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and a lack of motor control is very evident. Animals receiving CyPPA showed a
significant 7% increase in final failure using a student’s t-test (p = 0.03). Average
final failure for animals receiving CyPPA occurred at P128, while animals receiving
the vehicle control occurred at P120.
Final failure tracks “survival” of motor function and indicates when animals
lose their ability to balance and coordinate themselves on the rotarod (Figure 9).
Some labs use a functional time point like final failure as their “survival” criteria
because they believe it may be a more sensitive gauge (Lutz et al 2009). This
analysis in the form of a Kaplan-Meier curve shows the percentage of animals
running over time. Significant differences were found using the Cox’s proportional
F-Test (p = 0.03), indicating that animals receiving CyPPA retain motor function
longer as the disease advances.
In the latter stages of the study, disease progression is quite rapid and many
animals succumb to the illness (Figure 10). The survival analysis is then completed
on the animals. Survival is determined when animals fail the righting reflex test
within a 30 second period. On average animals receiving CyPPA showed a significant
8% increase in survival using a student’s t-test (p = 0.0063). On average animals
receiving CyPPA lived 136 days while animals receiving the vehicle control lived
126 days (a 10 day extension in survival).
A Kaplan-Meier curve was generated using the survival data and showed
significant differences for survival between the two groups (Figure 11). Significant
differences were found using a Cox’s Proportional F-Test (p = 0.007). The oldest
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animal receiving CyPPA survived for 152 days which was nearly 20 days longer than
the oldest Vehicle Control animal.
Study 1 Conclusions
Significant improvements in motor function and survival were found,
suggesting a slower disease progression. Animals receiving the 16 day treatment of
CyPPA presented extended motor function in the latter stages of the disease and an
increased likelihood that motor function would persist based on the final failure
analysis using the Kaplan Meier curve. Survival was also improved in the animals
receiving CyPPA, this 10 day increase equated to nearly an 8% change overall.
These results show that SK channels could be a potential drug target and
CyPPA may have therapeutic properties. These results also suggest that CyPPA is a
potential treatment for SOD1 mutant mice. To further assess its effects, we
compared CyPPA to Riluzole’s effects on survival and motor function of SOD mice.
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Motor Function
****

Figure 6: Motor Function – 16 Day Treatment of CyPPA Starting at P5 – P20
Graph showing average rotarod completion for animals in both treatment groups. Diamonds
represent average first failure for each group being dosed. Average first failure for the animals
receiving the vehicle control and CyPPA occurred at P111. No significant differences were present
testing first failure. Motor function for animals receiving CyPPA was significantly different from
P123 – P128 using the student’s t-test and from P125 – 128 using the Mann-Whitney U test.
Vehicle Control n = 13, CyPPA n =12; Data is Mean ± S.E.
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Rate of Motor Function Loss

Figure 7: Rate of Motor Function Loss – 16 Day Treatment of CyPPA starting at P5 – P20
Slope for animals receiving CyPPA was -0.0211 while animals receiving the vehicle control was 0.0349. Using a regression test we determined that motor function decline was significantly
different between the two groups, p-value 0.007. Vehicle Control n = 13, CyPPA n =12; Data is
Mean ± S.E.
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Figure 8: Final Failure – 16 Day Treatment of CyPPA starting at P5 – P20
Animals receiving CyPPA increased average final failure by 7%. Final Failure was significant when
analyzed using a student’s t-test (p = 0.03). Vehicle Control n = 13, CyPPA n =12; Data is Mean ±
S.E.
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Figure 9: Final Failure (Kaplan Meier) – 16 Day Treatment of CyPPA starting at P5 – P20
Animals receiving CyPPA showed significant survival improvements testing motor function using
Cox’s proportional F-Test (p = 0.03). Vehicle Control n = 13, CyPPA n =12;
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Figure 10: Survival – 16 Day Treatment of CyPPA starting at P5 – P20
Animals receiving treatment of CyPPA lived 10 days longer on average. Which equated to a
significant 8% increase (p = 0.006). Animal’s receiving CyPPA lived 136 days while animals
receiving the vehicle control lived 126 days on average. Vehicle Control n = 13, CyPPA n =12; Data
is Mean ± S.E.
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Figure 11: Survival (Kaplan-Meier) – 16 Day Treatment of CyPPA starting at P5 – P20
Animals receiving CyPPA showed significant extension in survival using Cox’s proportional F-Test,
p-value 0.007. The oldest CyPPA animal lived 152 days, nearly 20 days longer than the oldest
Vehicle Control animal
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Study 2 - 16 Day Treatment of Riluzole starting at P5 – P20
Riluzole was administered via once daily intraperitoneal injections at
concentration of 22 mg/kg. A concentration of 22 mg/kg was preferred over the
optimal dosage (44 mg/kg) reported in literature because when tested higher
concentrations lead to the death of the neonatal mice. The n for animals receiving
Riluzole and the vehicle control was 12.
Animals receiving Riluzole showed no significant differences in the first
failure analysis which was completed using a student’s t-test (p = 0.19). Average
first failure for animals receiving Riluzole occurred at P93 while animals receiving
the vehicle control occurred at P88 (Figure 12). Analysis of motor function was
completed by using a student’s t-test. Unfortunately, no differences were found
testing motor function.
A regression test was used to analyze the slope of motor function (Figure 13).
Analysis of the regression test showed no significant differences between the two
groups (p = 0.29). Slope for animals receiving Riluzole was -0.0144, R2 = 0.82,
whereas the slope for the animals receiving the vehicle control was -0.0183, R2 =
0.89.
The next analysis completed tested final failure (Figure 14). Again, no
significant differences were found between the two groups (p = 0.45). Average final
failure for the animals receiving Riluzole occurred at P121 while final failure for
animals receiving the vehicle control occurred at P119. Upon completion of the final
failure analysis, Kaplan-Meier curves were also analyzed for the final failure criteria
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(Figure 15). No significant differences were found when analyzing the Cox’s
proportional F-Test (p = 0.34).
Animals receiving Riluzole showed no changes in survival when assessing
means using a student’s t-test (p = 0.99). Survival for both the treatment and the
vehicle control groups occurred at P131 (Figure 16). A Kaplan-Meier curve was
generated and showed no significant differences for survival between the two
groups by using the Cox’s proportional F-Test (p = 0.37) (Figure 17).
Study 2 Conclusions
Riluzole administration showed no changes in either motor function or
survival. These results as well as the results from the preceding CyPPA study
suggest that drugs with specific SK-channel activation properties may have greater
therapeutic effects than non-specific drugs.
These short term neonatal studies were very beneficial for studying disease
mechanisms and pathogenesis. Interestingly, the major takeaways from these
neonatal studies is that SK channels seem to play a role in the disease mechanism
and that activation of SK channels may produce therapeutic effects. Given that
clinical drug treatment starts after ALS diagnosis, we then tested administration of
CyPPA at symptom onset.
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Motor Function

Figure 12: Motor Function – 16 Day Treatment of Riluzole starting at P5 – P20
Diamonds represent average first failure for each group being dosed. Average first failure for the
animals receiving the vehicle control occurred at P88 and Riluzole occurred at P93. No significant
differences were present testing first failure or motor function. Vehicle Control n = 12, Riluzole n
=12; Data is Mean ± S.E.
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Rate of Motor Function Loss

Figure 13: Rate of Motor Function Loss – 16 Day Treatment of Riluzole starting at P5 – P20
Slope for animals receiving Riluzole was -0.0144 while animals receiving the vehicle control was 0.0186. Using a regression test we determined that motor function decline was not significantly
different between the two groups. Vehicle Control n = 12, Riluzole n =12; Data is Mean ± S.E.
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Figure 14: Final Failure – 16 Day Treatment of Riluzole starting at P5 – P20
Animals receiving Riluzole treatment had no change in average final failure. Vehicle Control n =
12, Riluzole n =12; Data is Mean ± S.E.
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Figure 15: Final Failure (Kaplan-Meier) – 16 Day Treatment of Riluzole starting at P5 – P20
Animals receiving Riluzole showed no changes in motor function using Cox’s proportional F-Test.
Vehicle Control n = 12, Riluzole n =12; Data is Mean ± S.E.
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Figure 16: Survival: 16 Day Treatment of Riluzole starting at P5 – P20
Animals receiving Riluzole and the vehicle control presented no changes, Riluzole and Vehicle
Control animals on average lived 131 days. Vehicle Control n = 12, Riluzole n =12; Data is Mean ±
S.E.
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Figure 17: Survival (Kaplan-Meier) 16 Day Treatment of Riluzole starting at P5 – P20
Animals receiving Riluzole showed no changes in survival using Cox’s proportional F-Test. Vehicle
Control n = 12, Riluzole n =12; Data is Mean ± S.E.

50

155

CLINICALLY RELEVANT STUDIES
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Study 3 - Daily Treatment of CyPPA Starting at P90 – Death
CyPPA was administered via once daily intraperitoneal injections at
concentration of 14 mg/kg. We decided on this concentration because of the
therapeutic effects observed from the previous study (16 Day Treatment of CyPPA
at P5 – P20) which used the same concentration and we wanted our drug
concentration to remain consistent throughout the studies. The n for animals
receiving CyPPA was 13 and n for animals receiving the vehicle control was 14.
Animals receiving daily treatments of CyPPA presented no significant
differences in the first failure analysis which was completed using a student’s T-test
(p = 0.09). Average first failure for animals receiving daily treatments of CyPPA
occurred at P91 while animals receiving the vehicle control occurred at P87.
Analysis of motor function was completed by using a student’s T-test (Figure 18).
No differences were found testing motor function.
Slope for animals receiving daily treatments of CyPPA was -0.0211, R2 = 0.92.
Slope for animals receiving the vehicle control was -0.0172, R2 = 0.87. Analysis of
the regression test again showed no significant changes (p = 0.158) (Figure 19).
The next criteria analyzed tested final failure or the time in which of gross
motor deficits and a lack of motor control become present (Figure 20). Final failure
was not significant between the two groups using a student’s t-test (p = 0.19).
Average final failure for animals receiving daily treatments of CyPPA occurred at
P123 while animals receiving the vehicle control occurred at P127. To complement
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the final failure t-test, Kaplan-Meier survival curves were created (Figure 21). No
significant differences were found using the Cox’s proportional F-Test (p = 0.9).
In the later stages of the study, disease progression is quite rapid and many
animals succumb to the disease (Figure 22). Survival analysis using the student’s ttest (p = 0.23) and the Kaplan-Meier (p = 0.23) analysis showed no differences
between the two groups (Figure 23).
Study 3 Conclusions
Results from the third study did not show beneficial effects that were present
in the 16 day CyPPA neonatal study. We hypothesized that treatment with CyPPA
during symptom onset would produce some therapeutic effect. Given that daily
administration of SK-channel activators reduce MN firing frequency, daily
administration could mask the potential beneficial effects of motor function. We
therefore decided to test short-term administration of CyPPA at symptom onset
which occurs around P90.
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Motor Function

Figure 18: Motor Function – Daily Treatment of CyPPA starting at P90 - Death
Diamonds represent average first failure for each group being tested. Average first failure for the
animals receiving the vehicle control occurred at P87 and CyPPA occurred at P91. No significant
differences were present testing first failure or motor function. Vehicle Control n = 14, CyPPA n
=13; Data is Mean ± S.E.
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Rate of Motor Function Loss

Figure 19: Rate of Motor Function Loss – Daily Treatment of CyPPA starting at P90 - Death
Slope for animals receiving CyPPA was -0.0211 while animals receiving the vehicle control was 0.0172. Using a regression test we determined that motor function decline was not different.
Vehicle Control n = 14, CyPPA n =13; Data is Mean ± S.E.

55

Final Failure

13
@

14

Figure 20: Final Failure – Daily Treatment of CyPPA starting at P90 – Death
Animals receiving CyPPA had no change in average final failure. Vehicle Control n = 14, CyPPA n
=13; Data is Mean ± S.E.
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Figure 21: Final Failure (Kaplan-Meier) – 16 Day Treatment of CyPPA starting at P90 – Death
Kaplan-Meier curve showing percent of animals still running on the rotarod. Animals receiving
CyPPA showed no changes in motor function using Cox’s proportional F-Test. Vehicle Control n =
14, CyPPA n =13; Data is Mean ± S.E.
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Figure 22: Survival – Daily Treatment of CyPPA starting at P90 – Death
Animals receiving CyPPA and the vehicle control presented no changes in Survival. On average
animals receiving CyPPA lived for 130 days and Vehicle Control animals lived 134 days. Vehicle
Control n = 14, CyPPA n =13; Data is Mean ± S.E.
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Figure 23: Survival (Kaplan-Meier) - Daily Treatment of CyPPA tarting at P90 – Death
Kaplan-Meier curve showing percent of animal’s surviving. Animals receiving CyPPA showed no
changes in survival using Cox’s proportional F-Test. Vehicle Control n = 14, CyPPA n =13; Data is
Mean ± S.E.
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Study 4 - 7 Day Treatment of CyPPA starting at P90 – P96
CyPPA was administered via once daily intraperitoneal injections at
concentration of 14 mg/kg. We decided on this concentration because of the
therapeutic effects observed from a previous study (16 Day Treatment of CyPPA at
P5 – P20) which used the same concentration and we wanted our drug
concentration to remain consistent throughout each of the studies. The n for
animals receiving CyPPA was 14 and n for animals receiving the vehicle control was
14.
Animals receiving short term treatments of CyPPA showed no significant
differences in first failure (p = 0.06). Average first failure for animals receiving the
temporary treatment of CyPPA occurred at P101 (Figure 24). Average first failure
for animal’s receiving the vehicle control occurred at P93. To our excitement, we
observed several time points along the motor function graph with significant
improvements. Animals receiving CyPPA showed sustained motor function as the
disease progressed. Significant differences were found using a student’s t-test and
occurred from P92 – P105 and P112 – P119 (P92 – P105, p ≤ 0.05; P112 – P119, p ≤
0.03). Analysis of the Mann-Whitney U test also showed significant improvements in
motor function between the treatment and control vehicle groups from P94 (p ≤
0.032), P97 - P100 (p ≤ 0.027), P102 - P103 (p ≤ 0.014), and P114 - P118 (p ≤
0.022).
After finding differences between each day the animals received CyPPA. A
regression test was used to analyze slope of motor function (Figure 25). Analysis of
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the regression test showed significant differences between the slopes for the
temporary treatments of CyPPA and the vehicle control. Slope for the animals
receiving CyPPA was -0.0207, R2 = 0.92, while vehicle control animals had a slope of
-0.0263, R2 = 0.92 (p = 0.029).
The next analysis completed tested final failure (Figure 26). The
improvements in motor function and rate of motor function loss suggested that the
final failure criteria may also be significant. Final failure for the animals receiving
CyPPA occurred at P126 while animals receiving the vehicle control occurred at
P119. Unfortunately, this 5% increase did not to reach significance (p = 0.06).
However, generation of the Kaplan-Meier curve did show significant differences
amongst the percentages of animals running over time (Figure 27). Significant
differences were found using the Cox’s proportional F-Test (p = 0.03). This
suggested that animals receiving temporary CyPPA treatments maintain motor
function as the disease progresses and have a higher probability of motor function
enduring during the latter stages of the disease.
Unlike the first study, this final study using CyPPA did not extend survival in
the SOD1 mutants (Figure 28). On average animals treated with CyPPA lived 135
days while vehicle control animals lived 129 days (p = 0.25). The Kaplan-Meier
curve also showed no significant differences for survival between the two groups (p
= 0.06) (Figure 29). It is interesting to note that in this study we had an animal who
survived the longest out of any study. This animal lived for 162 days which was
nearly 20 days longer than the oldest vehicle control animal.
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Clinically Relevant Conclusions
Chronic treatments of CyPPA had no therapeutic effect. This lack of beneficial
effects might have occurred because CyPPA does present some acute motor effects
after administration. In a preliminary study, it was found that thirty minutes after
drug administration animals injected with CyPPA would become lethargic and
motor function was significantly reduced. For all of the clinically relevant studies,
animals were given drug after behavioral testing to avoid any changes to motor
output and prevent variances in the data. It is likely that the drug did not directly
affect motor performance during testing. However, continuous dosing with CyPPA
during the daily treatment study, potentially kept the animals in a poor state, thus
producing no therapeutic effects.
In contrast, short term treatments with the same drug produced significant
improvements in motor function though survival was unchanged. In the latter
stages of the disease, motor function was sustained in the animals receiving the
treatment and they had a higher probability of retaining their motor function later
in the disease. This suggests that CyPPA is having some therapeutic effect on the
animals, possibly preserving MNs.
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Motor Function
******
****

Figure 24: Motor Function – 7 Day Treatment of CyPPA starting at P90 – P96
Diamonds represent average first failure for each group being dosed. Average first failure for the
animals receiving the vehicle control was 93 days while CyPPA occurred at P101. No significant
differences were present testing first failure, though the p-value was 0.06. Motor function for
animals receiving CyPPA was significantly different from P92 – P105 and P112 – P119usign the
student’s t-test.The -Whitney U test also showed significant improvements in motor function
between the treatment and control vehicle groups from P94 (p ≤ 0.032), P97 - P100 (p ≤ 0.027),
P102 - P103 (p ≤ 0.014), and P114 - P118 (p ≤ 0.022). Significance was determined when p-value
was <0.05. Vehicle Control n = 14, CyPPA n =14; Data is Mean ± S.E.
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Rate of Motor Function Loss

Figure 25: Rate of Motor Function Loss – 7 Day Treatment of CyPPA starting at P90 – P96
Slope for animals receiving CyPPA was -0.0207 while animals receiving the vehicle control was 0.0263. Using a regression test we determined that motor function decline was significantly
different between the two groups, p-value was 0.029. Vehicle Control n = 14, CyPPA n =14; Data is
Mean ± S.E.
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Figure 26: Final Failure – 7 Day Treatment of CyPPA starting at P90 – P96
Animals receiving CyPPA treatment increased average final failure by 5%. Average final failure for
the animals receiving the vehicle control was 119 days while CyPPA occurred at P126. No
significant differences were present testing final failure. Vehicle Control n = 14, CyPPA n =14; Data
is Mean ± S.E.
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Figure 27: Final Failure –7 Day Treatment of CyPPA starting at P90 – P96
Animals receiving CyPPA showed significant improvements in motor function by staying on the
rotarod for an extended number of days. Significant differences were found using Cox’s
proportional F-Test, p-value 0.0321. Vehicle Control n = 14, CyPPA n =14; Data is Mean ± S.E.
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Figure 28: Survival – 7 Day treatment of CyPPA starting at P90 – P96
Animals receiving CyPPA treatment increased survival by 4%. Average survival for the animals
receiving the vehicle control was 130 days while CyPPA occurred at P134. No significant
differences were found. Vehicle Control n = 14, CyPPA n =14; Data is Mean ± S.E.
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Figure 29: Survival (Kaplan-Meier) – 7 Day Treatment of CyPPA starting at P90 - P96
Animals receiving CyPPA showed no significant improvements in survival using Cox’s proportional
F-Test (p = 0.06). The oldest CyPPA animal lived 162 days (best of all studies), 20 days longer than
the oldest surviving vehicle control animal. Vehicle Control n = 14, CyPPA n =14; Data is Mean ±
S.E.
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Table 3: Comparison of All Drug Studies
Table depicting all motor and survival criteria for each study completed. * denotes significance and p-values < 0.05.
Data is Mean ± S.E.
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DISCUSSION
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To date the underlying mechanism which initiates MN death in ALS is still
unknown. However, there is evidence that hyperexcitability and excitotoxicity play a
key role in the disease mechanism. Previous studies from our lab used
computational modeling as well as immunohistochemistry to test specific channel
types. Our modeling predicted that SK channels become downregulated and
immunohistochemistry showed a decrease in SK cluster density and area in the
SOD1-G93A mutant (Elbasiouny et al, unpublished and Dukkipati, 2016). It is well
known that SK channels mediate the mAHP regulating cell excitability (Lam et al.,
2013). In the disease, it could be possible that a decrease in these channel types may
lead to increased cell firing, hyperexcitability, Ca2+ overload and eventual cell death
due to excitotoxicity. In our studies, drug administration with short term 16 day
neonatal (P5 – P20) drug interventions with CyPPA produced significant
improvements in both motor function and survival. While, short term 7 day
treatments with CyPPA during symptom onset (P90 – P96) also produced significant
improvements in motor function.
Our first study which administered CyPPA at neonatal time point (P5-P20)
showed significant improvements in motor function and survival. Animals receiving
the treatment of CyPPA had 5 days where motor function was significantly different
(Figure 6,Table 3). CyPPA also produced a lower slope compared to its vehicle
control, suggesting a reduced rate of motor function loss (Figure 7). Both analyses of
final failure and the survival criteria produced significant differences in the favor of
CyPPA (Figure 8,Figure 9,Figure 10,Figure 11). In support of our findings, a study
from 2008 suggested that SK activation by either NS309 or CyPPA may have
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neuroprotective function as they provided protection against glutamate-induced
excitotoxicity in primary cortical neurons (Dolga et al., 2008). Our data and this
information suggests that activation of SK channels by CyPPA may reduce the effects
of excitotoxicity, alleviating symptoms associated with the disease, thus leading to
the improvements we have reported.
CyPPA also produced significant motor function improvements during the
clinically relevant time point, though these results were limited to the short term (7Day) treatment. Overall, chronic long term treatments showed no changes in motor
function or survival. We think this phenomenon was observed because CyPPA has
acute motor effects, which significantly impairs motor output after injection. Since
CyPPA has been shown to increase mAHPs which result in a reduction of cell firing
rate. Continuous administration of CyPPA and the subsequent reduction of MN firing
likely left animals in a weak state. Animals kept in this state might have become
more vulnerable to disease changes, thus hampering any therapeutic effect of the
drug. On the other hand, short term treatments showed significant improvements.
Motor function and rate of motor function loss were all improved compared to the
vehicle control and the daily studies (Figure 18Figure 19Figure 24 ,Figure 25 and
Table 3). Our 7 day treatments also produced significant improvements in the final
failure Kaplan-Meier analysis (Figure 9). Unfortunately, most of the other analysis
criteria from the 7 day study produced no significant differences. First failure, final
failure, and the survival (Kaplan-Meier) analysis all presented p-values of 0.06. It is
interesting that motor function was improved in the short term treatment even
though the long term treatment presented no changes. The improvement from the
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short term treatments suggests that CyPPA may induce functional plasticity. The
short term 7 day treatments of CyPPA may have allowed for a metabolic break,
giving the MNs a chance to recover from excitotoxicity, Ca2+ overload, increased
excitability, causing them rejuvenate. These changes could have harbored a
protective therapeutic effect on MNs as wells SK channels, preserving motor
function. Protection of these channels might have led to the normalization of APs to
a state which is more reminiscent of the pre-symptomatic state. A return to this
state would have allowed surviving MNs to function normally, staving off disease
related symptoms, thus producing the significant improvements in motor function.
This plasticity may have allowed MNs to adapt to the drug effects created by CyPPA,
producing the therapeutic effects we observed. Conversely, it is also possible that
continuous drug administration with CyPPA from the daily study caused numerous
health issues to these mice. It is unknown what actions CyPPA has on the liver,
respiratory system and cardiovascular systems and so daily interventions with this
drug might have caused the lack of change in motor function or survival
The most significant results from this project were the 16 day treatment of
CyPPA at P5 and the 7 day treatment with CyPPA at P90. When we compared our
results from these studies we did find some similarities. Motor function and rate of
motor function loss were both improved (Figure 6,Figure 7,Figure 8Figure 24,Figure
25, Figure 27 and Table 3) again suggesting that SK channels and treatment with

CyPPA are suited for protecting against excitotoxic injury (Benítez et al., 2011).
Unlike the neonatal study, no improvements in survival were observed during the
clinically relevant time point. During development there are a plethora of MN’s. If
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CyPPA has therapeutic properties it is likely that these MNs become more robust
with treatment during development and end up less affected by disease changes.
Conversely, treatment with CyPPA during symptom onset starts long after MN death
has begun. With a limited number of MNs left during the clinically relevant time
point, the beneficial effects of CyPPA might have been diminished leading to
improvements in motor function but no changes in survival.
When we compated CyPPA with Riluzole we saw that drug administration
with Riluzole presented no effects on motor function or survival in our neonatal
studies. Interestingly, previous literature has shown significant increases in survival
when adult G93A-H mutants are treated with Riluzole (Gurney et al., 1998). There
are vast differences in the Gurney study compared to our study. Gurney et al treated
adult animals with Riluzole from P42 until death at a concentration of 44mg/kg
where as our study treated neonatal animals from P5-P20 at a concentration of
22mg/kg. Neonatal animals given a dosage of 44mg/kg and 33mg/kg ended dying
from these high concentrations and so a lower concentration of Riluzole was used in
our studies. The lack of improvements in motor function and survival demonstrates
that neonatal interventions with Riluzole are not therapeutic and that drug
treatment with a specific channel activator may be more beneficial than treatment
with a non-specific drug. Riluzole targets numerous channel types along with SK
channels (Cao et al., 2002). However, Pedarzani et al 2005 showed that CyPPA is far
more potent than Riluzole when activating SK channels (Pedarzani et al., 2005). This
information along with our data, which shows improvements in both motor function
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and survival by CyPPA, suggests that activation by specific drug therapies can be
more beneficial than activation by non-specific drugs.
Completion of these studies suggests that CyPPA and SK channels may have
therapeutic properties. These changes could have lead to the improvements in
motor function and survival. Beneficial effects produced by CyPPA may have also
occurred due to an increased number of SK channels, increased SK expression or
conductance through the channels. These increases could reduce MN firing rate and
mAHP, reducing the effects of hyperexcitability and excitotoxicity. The reduction of
these pathologies in G93A- H mutants may have led to the protection of MNs
thereby improving motor function as well as survival in some of our studies. In
support of our findings, previous studies have shown that SK channel activation by
CyPPA could be considered as a therapy for glutamate-induced excitotoxicity
(Benítez et al., 2011; Dolga et al., 2008) which would also ameliorate disease related
symptoms. Given that behavioral testing was completed for these studies
determining the preservation of MNs is difficult. It is possible that treatment with
CyPPA during development could strengthen the respiratory system as well as
producing stronger skeletal muscle. If this is the case, these changes might have also
produced the improvements in motor function and survival.
There are several limitations in our studies. First, the half-life of CyPPA is
unknown. Pharmacokinetic data as well as a dose response curve would have
ensured proper dosing of the drug and potentially more favorable outcomes from
these experiments. Without this pharmacokinetic data, choosing a concentration
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which could produce therapeutic effects was just based on concentrations in
literature. A concentration of 14mg/kg was settled upon and we did see significant
effects. It is possible that far greater benefits could have been produced if an optimal
dosage was obtained. Improvements in motor function were found at this
concentration in the 16 day treatment of CyPPA commencing at P5 and the 7 day
treatments of CyPPA starting at P90. Moreover, the 16 day neonatal treatments of
CyPPA also prolonged survival in our SOD1 mutants. The presence of
pharmacokinetic data would have guided our efforts in selecting an optimal dosing
concentration. Even though CyPPA produced therapeutic effects we are unsure
whether these effects are mediated via SK channels on MNs . SK channels are found
in numerous cell types. Our lab currently has ongoing experiments to test whether
CyPPA effects are mediated through MNs. Published data support the idea of CyPPA
as a therapy for glutamate-induced excitotoxicity (Dolga et al 2008) and there is
evidence showing that treatment with CyPPA could improve motor function in other
neurodegenerative diseases which share similarities to ALS (Benítez et al 2011).
Another limitation arose during the Riluzole study. Gurney et al 1998
suggested the optimal dosage for Riluzole in adults SOD1 mutants should be
44mg/kg. Initially we started with this concentration for our neonatal injections but
we were met with complications. 44mg/kg was too high of a concentration for pups
and several of the animals did not survive the treatment. The concentration was
then dropped to 33mg/kg and pups were still being lost. Finally, at a concentration
of 22mg/kg, half of the optimal dosage in adults, pups were able to survive the full
16 day dosing period.
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For future studies it would be imperative to test other SK channel activators
to ensure the beneficial effects are not limited to one drug. Conversely, instead of
testing SK channel activators it would be interesting to test an SK channel blocker as
well. Apamin, a neurotoxin found in bee venom selectively blocks SK channels,
eliminating the mAHP and increasing cell firing rate (Castle, Haylett, & Jenkinson,
1989; Herrik et al., 2012). It would be interesting to see if ALS symptoms become
exacerbated when SK channels become blocked and if our SOD1 mutants become
symptomatic earlier.
There have been some criticisms about the G93A-H transgenic line. Using a
transgenic line with that has longer disease progression such as the G93A-L or the
G85R lines might increase the understanding of disease mechanism and could
potentially provide insight into other pathologies which might become altered.
Finally, the search for early diagnosis has been an ongoing struggle in this field.
Using various techniques, such as nerve conduction studies, electrical impedance
myography (EIM), Dual-energy X-ray absorptiometry (DEXA) ( which measures lean
body mass), ultrasound, histology or electrophysiology may uncover novel
biomarkers. Enabling early diagnosis and allowing patients to receive treatments in
a timely manner, before symptoms become too severe.
In conclusion drug administration with CyPPA produced significant
improvements in both motor function and survival. Short teom neonatal drug
administration and short term drug administration during symptom onset proved
to be most beneficial suggesting that activation of SK channels via CyPPA can
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produce therapeutic effects and that SK channels are indeed viable drug targets.
Another interesting outcome from this study was that neonatal treatment with
Riluzole did not have an impact on survival or motor function while CyPPA did. This
suggests that neonatal interventions with Riluzole are not beneficial but more
importantly that channel specificity could be required for therapeutic effectiveness.
Perhaps the most encouraging fact about this drug is that it has been previously
shown to improve motor function in other neurodegenerative diseases such as SCA2
and SMA (Dimitriadi et al., 2013; Kasumu et al., 2012). While CyPPA is not yet FDA
approved, positive results like these suggest that in time CyPPA may become a
potential therapy for patients suffering from ALS.
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